MedTrace Logo

Treatment of Advanced Gastrointestinal Cancer in a Phase I/II Trial With Modified Autologous MSC_apceth_101

NCT02008539 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2017-03-27

No results posted yet for this study

Summary

To evaluate the safety and tolerability of MSC\_apceth\_101.

Conditions

  • Advanced Gastrointestinal Cancer

Interventions

DRUG

MSC_apceth_101

Sponsors & Collaborators

  • Apceth GmbH & Co. KG

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2016-09-07
Completion
2016-09-07

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02008539 on ClinicalTrials.gov